REG - Sareum Holdings PLC - Notice of AGM, Annual Report and Accounts

Sareum HoldingsAnnouncement

24/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221124:nRSX4084Ha&default-theme=true

RNS Number : 4084H  Sareum Holdings PLC  24 November 2022

Sareum Holdings PLC

("Sareum" or the "Company")

Notice of AGM, Annual Report and Accounts

 

Cambridge, UK, 24 November 2022 - Sareum Holdings plc (AIM: SAR), a
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, today announces that the Company's Annual
General Meeting ("AGM") will be held at 10.00 a.m. on 16 December 2022 at the
offices of Peel Hunt LLP, 7th Floor, 100 Liverpool St, London EC2M 2AT.

The AGM will also be webcast via the Investor Meet Company ("IMC") platform.
Shareholders who wish to follow the meeting via the IMC platform should
register with IMC at
www.investormeetcompany.com/sareum-holdings-plc/register-investor.

Shareholders are invited to listen to the meeting via the IMC platform and
they will be able to raise questions with the Chairman, Chief Executive
Officer and Chief Scientific Officer in a Q&A session to be held
immediately after the AGM.  Shareholders are reminded that this will not
constitute attendance at the AGM and shareholders will not be able to vote on
the day.

Shareholders intending to vote should do so via the shareholder portal at
www.signalshares.com where details of the procedure are shown. Alternatively,
shareholders may request a paper form of proxy from our registrars, Link
Group.

The notice of AGM, along with a copy of the Company's annual report and
accounts for the year ended 30 June 2022, will be posted today to those
shareholders who requested a hard copy. A copy of both documents will also be
available on the Company's website www.sareum.com.

 

- Ends -

 

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Alexandra Harrison, Head of IR                      ir@sareum.co.uk (mailto:ir@sareum.co.uk)

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Oliver Duckworth                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   0203 709 5700

 

About Sareum

Sareum Holdings (AIM:SAR) is a  biotechnology company developing next
generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases with an initial
focus on psoriasis. Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor
with a potential application for cancer immunotherapy.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABJBRTMTMTBIT